| Identification | Back Directory | [Name]
Benzeneacetamide, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-4-[[6-[4-(methylsulfonyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- | [CAS]
2484919-71-1 | [Synonyms]
RET-IN-19
Benzeneacetamide, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-4-[[6-[4-(methylsulfonyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- | [Molecular Formula]
C28H28N6O4S | [MOL File]
2484919-71-1.mol | [Molecular Weight]
544.62 |
| Hazard Information | Back Directory | [Uses]
RET-IN-19 (compound 59) is a potent RET inhibitor, with IC50 values of 6.8 and 13.51 nM against RET-wt and RET V804M, respectively. RET-IN-19 shows anticancer activity. RET-IN-19 can be used for non-small cell lung cancer (NSCLC) research[1]. | [IC 50]
EGFR: 56.78 ± 4. μM (IC50); Aurora A: 0.242 ± 0. μM (IC50); Aurora B: 0.536 ± 45 μM (IC50); MAP4K4: 3.428 ± 0. μM (IC50) | [References]
[1] Lakkaniga NR, et al. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation. Eur J Med Chem. 2020 Nov 15;206:112691. DOI:10.1016/j.ejmech.2020.112691 |
|
|